UK markets closed

Abcam plc (ABC.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,179.00+11.00 (+0.94%)
At close: 04:35PM BST
Full screen
Previous close1,168.00
Open1,192.00
Bid1,179.00 x 0
Ask1,180.00 x 0
Day's range1,173.00 - 1,203.00
52-week range11.05 - 1,780.00
Volume208,898
Avg. volume312,604
Market cap2.699B
Beta (5Y monthly)0.71
PE ratio (TTM)620.53
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date19 Mar 2020
1y target estN/A
  • Business Wire

    Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

    CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif., February 01, 2022--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic an

  • Globe Newswire

    29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

    CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period. SUMMARY PERFORMANCE 12 mont

  • Globe Newswire

    Abcam to Acquire BioVision for $340 million

    CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and distributor of life